Gene targeting in human somatic cells

Source Book of Models for Biomedical Research

Volumn , Issue , 2008, Pages 509-525

  Hendrickson, Eric A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

DNA double strand breaks; Gene knockouts; Gene targeting; Gene therapy; HCT116 cells; Homologous recombination; NALM 6 cells; Nonhomologous end joining; Recombinant adeno associated virus

Indexed keywords

EID: 42249085637     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-285-4_53     Document Type: Chapter

References (148)

1. Sedivy JM, Joyner A. Gene Targeting. New York: W.H. Freeman and Company, 1992.
2. Sorrell DA, Kolb AF. Targeted modification of mammalian genomes. Biotechnol Adv 2005;23:431-469.
3. Yu Y, Bradley A. Engineering chromosomal rearrangements in mice. Nat Rev Genet 2001;2:780-790.
4. Park F, Gow KW. Gene therapy: Future or fl op. Pediatr Clin North Am 2006;53:621-638.
5. Cahill D, Connor B, Carney JP. Mechanisms of eukaryotic DNA double strand break repair. Front Biosci 2006;11:1958-1976.
6. van Veelen L, Wesoly J, Kanaar R. Biochemical and cellular aspects of homologous recombination. In: Seide W, Kow YW, Doetsch P, Eds. DNA Damage Recognition. New York: Taylor & Francis Group, 2006:581-607.
7. Hefferin ML, Tomkinson AE. Mechanism of DNA double-strand break repair by nonhomologous end joining. DNA Repair 2005;4:639-648.
8. Sedivy JM, Vogelstein B, Liber HL, Hendrickson EA, Rosmarin A. Gene targeting in human cells without isogenic DNA. Science 1999;283:9a.
9. Vasileva A, Jessberger R. Precise hit: Adeno-associated virus in gene targeting. Nat Rev Microbiol 2005;3:837-847.
10. Adachi N, So S, Iiizumi S, et al. The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination. DNA Cell Biol 2006;25:19-24.
11. Sonoda E, Hochegger H, Saberi A, Taniguchi Y, Takeda S. Differential usage of nonhomologous end-joining and homologous recombination in double strand break repair. DNA Repair 2006;5: 1021-1029.
12. Roth DB, Wilson JH. Relative rates of homologous and nonhomologous recombination in transfected DNA. Proc Natl Acad Sci USA 1985;82:3355-3359.
13. Lieber MR, Ma Y, Kefei Y, Pannicke U, Schwarz K. The mechanism of vertebrate nonhomologous DNA end joining and its role in immune system gene rearrangements. In: Seide W, Kow YW, Doetsch P, Eds. DNA Damage Recognition. New York: Taylor & Francis Group, 2006:609-627.
14. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987;51:503-512.
15. Lee SE, Mitchell RA, Cheng A, Hendrickson EA. Evidence for DNA-PK-dependent and-independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle. Mol Cell Biol 1997;17:1425-1433.
16. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA doublestrand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497-5508.
17. Hendrickson EA, Huffman JL, Tainer JA. Structural aspects of Ku and the DNA-dependent protein kinase complex. In: Seide W, Kow YW, Doetsch P, Eds. DNA Damage Recognition. New York: Taylor & Francis Group, 2006:629-684.
18. Getts RC, Stamato TD. Absence of a Ku-like DNA end binding activity in the xrs double-strand DNA Repair-defi cient mutant. J Biol Chem 1994;269:15981-15984.
19. Liang F, Romanienko PJ, Weaver DT, Jeggo PA, Jasin M. Chromosomal double-strand break repair in Ku80-deficient cells. Proc Natl Acad Sci USA 1996;93:8929-8933.
20. Inamdar KV, Yu Y, Povirk LF. Resistance of 3'-phosphoglycolate DNA ends to digestion by mammalian DNase III. Radiat Res 2002;157:306-311.
21. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen. Cell 1993;72:131-142.
22. Suwa A, Hirakata M, Takeda Y, Jesch SA, Mimori T, Hardin JA. DNA-dependent protein kinase (Ku protein-p350 complex) assembles on double-stranded DNA. Proc Natl Acad Sci USA 1994;91:6904-6908.
23. DeFazio LG, Stansel RM, Griffith JD, Chu G. Synapsis of DNA ends by DNA-dependent protein kinase. EMBO J 2002;21:3192-3200.
24. Weterings E, Verkaik NS, Bruggenwirth HT, Hoeijmakers JH, van Gent DC. The role of DNA dependent protein kinase in synapsis of DNA ends. Nucleic Acids Res 2003;31:7238-7246.
25. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O. Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 2006;22(4):511-519.
26. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune defi ciency. Cell 2001;105:177-186.
27. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002;108:781-794.
28. Moshous D, Callebaut I, de Chasseval R, et al. The V(D)J recombination/ DNA Repair factor Artemis belongs to the metallo-betalactamase family and constitutes a critical developmental checkpoint of the lymphoid system. Ann NY Acad Sci 2003;987:150-157.
29. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA doublestrand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol 1997;7:588-598.
30. McElhinny SAN, Snowden CM, McCarville J, Ramsden DA. Ku recruits the XRCC4 ligase IV complex to DNA ends. Mol Cell Biol 2000;20:2996-3003.
31. Teo SH, Jackson SP. Lif1p targets the DNA ligase Lig4p to sites of DNA double-strand breaks. Curr Biol 2000;10:165-168.
32. Li Z, Otevrel T, Gao Y, et al. The XRCC-4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell 1995;83:1079-1089.
33. Gao Y, Frank KM, Dikkes P, et al. A critical role for DNA endjoining proteins in both lymphogenesis and neurogenesis. Cell 1998;95:891-902.
34. Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006;124:301-313.
35. Buck D, Malivert L, de Chasseval R, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodefi ciency with microcephaly. Cell 2006;124:287-299.
36. Hopfner K-P. The Mre11/Rad50/Nbs1 complex. In: Seide W, Kow YW, Doetsch P, Eds. DNA Damage Recognition. New York: Taylor & Francis Group, 2006:705-721.
37. Moreau S, Morgan EA, Symington LS. Overlapping functions of the Saccharomyces cerevisiae Mre11, Exo1 and Rad27 nucleases in DNA metabolism. Genetics 2001;159:1423-1433.
38. Iftode C, Daniely Y, Borowiec JA. Replication protein A (RPA): The eukaryotic SSB. Crit Rev Biochem Mol Biol 1999;34:141-180.
39. Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in mammals. Acta Med Okayama 2005;59:1-9.
40. Sung P, Trujillo KM, Van Komen S. Recombination factors of Saccharomyces cerevisiae. Mutat Res 2000;451:257-275.
41. Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett 2005;219:125-135.
42. Sugiyama T, Kowalczykowski SC. Rad52 protein associates with replication protein A (RPA)-single-stranded DNA to accelerate Rad51-mediated displacement of RPA and presynaptic complex formation. J Biol Chem 2002;277:31663-31672.
43. Heyer WD, Li X, Rolfsmeier M, Zhang XP. Rad54: The Swiss Army knife of homologous recombination? Nucleic Acids Res 2006;34:4115-4125.
44. Solinger JA, Kiianitsa K, Heyer WD. Rad54, a Swi2/Snf2-like recombinational repair protein, disassembles Rad51 : dsDNA fi laments. Mol Cell 2002;10:1175-1188.
45. Hastings PJ, McGill C, Shafer B, Strathern JN. Ends-in vs. ends-out recombination in yeast. Genetics 1993;135:973-980.
46. Sharma S, Doherty KM, Brosh RM Jr. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem J 2006;398:319-337.
47. Liu Y, Masson JY, Shah R, O'Regan P, West SC. RAD51C is required for Holliday junction processing in mammalian cells. Science 2004;303:243-246.
48. Liu Y, West SC. Happy Hollidays: 40th anniversary of the Holliday junction. Nat Rev Mol Cell Biol 2004;5:937-944.
49. Zheng H, Hasty P, Brenneman MA, et al. Fidelity of targeted recombination in human fibroblasts and murine embryonic stem cells. Proc Natl Acad Sci USA 1991;88:8067-8071.
50. Yanez RJ, Porter AC. Influence of DNA delivery method on gene targeting frequencies in human cells. Somat Cell Mol Genet 1999;25:27-31.
51. Yanez RJ, Porter AC. Gene targeting is enhanced in human cells overexpressing hRAD51. Gene Ther 1999;6:1282-1290.
52. Bunz F, Fauth C, Speicher MR, et al. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 2002; 62:1129-1133.
53. Hendrie PC, Hirata RK, Russell DW. Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice. J Virol 2003;77:13136-13145.
54. Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003;21:319-321.
55. Trobridge G, Hirata RK, Russell DW. Gene targeting by adenoassociated virus vectors is cell-cycle dependent. Hum Gene Ther 2005;16:522-526.
56. So S, Nomura Y, Adachi N, et al. Enhanced gene targeting effi ciency by siRNA that silences the expression of the Bloom syndrome gene in human cells. Genes Cells 2006;11:363-371.
57. Jasin M, Elledge SJ, Davis RW, Berg P. Gene targeting at the human CD4 locus by epitope addition. Genes Dev 1990;4:157-166.
58. Manjunath N, Johnson RS, Staunton DE, Pasqualini R, Ardman B. Targeted disruption of CD43 gene enhances T lymphocyte adhesion. J Immunol 1993;151:1528-1534.
59. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-5190.
60. Grawunder U, Zimmer D, Fugmann S, Schwarz K, Lieber MR. DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes. Mol Cell 1998;2:477-484.
61. Miyagawa K, Tsuruga T, Kinomura A, et al. A role for RAD54B in homologous recombination in human cells. EMBO J 2002;21: 175-180.
62. Ghosh G, Li G, Myung K, Hendrickson EA. The lethality of Ku86 loss-of-function mutations in human cells is p53-independent. Radiat Res 2007;167(1):66-79.
63. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell typespecifi c gene targeting. Science 1994;265:103-106.
64. Li G, Nelsen C, Hendrickson EA. Ku86 is essential in human somatic cells. Proc Natl Acad Sci USA 2002;99:832-837.
65. Topaloglu O, Hurley PJ, Yildirim O, Civin CI, Bunz F. Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res 2005;33:e158.
66. Iiizumi S, Nomura Y, So S, et al. Simple one-week method to construct gene-targeting vectors: Application to production of human knockout cell lines. Biotechniques 2006;41:311-316.
67. Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA 1988;85:5166-5170.
68. Kolb AF. Genome engineering using site-specific recombinases. Cloning Stem Cells 2002;4:65-80.
69. Austin S, Ziese M, Sternberg N. A novel role for site-specifi c recombination in maintenance of bacterial replicons. Cell 1981;25: 729-736.
70. Couedel C, Mills KD, Barchi M, et al. Collaboration of homologous recombination and nonhomologous end-joining factors for the survival and integrity of mice and cells. Genes Dev 2004;18:1293-1304.
71. Celli GB, Denchi EL, de Lange T. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat Cell Biol 2006;8:885-890.
72. Traverso G, Bettegowda C, Kraus J, et al. Hyper-combination and genetic instability in BLM-deficient epithelial cells. Cancer Res 2003;63:8578-8581.
73. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: Partners in checkpoint signaling. Science 2001;294:1713-1716.
74. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal betaglobin locus by homologous recombination. Nature 1985;317:230-234.
75. Montrose-Rafizadeh C, Kole J, Bartkowski LM, et al. Gene targeting of a CFTR allele in HT29 human epithelial cells. J Cell Physiol 1997;170:299-308.
76. Williams SR, Ousley FC, Vitez LJ, DuBridge RB. Rapid detection of homologous recombinants in nontransformed human cells. Proc Natl Acad Sci USA 1994;91:11943-11947.
77. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282: 1497-1501.
78. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fi broblasts. Science 1997;277:831-834.
79. Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974;33:1027-1033.
80. Geiser AG, Anderson MJ, Stanbridge EJ. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res 1989;49:1572-1577.
81. Farese RV Jr, Flynn LM, Young SG. Modification of the apolipoprotein B gene in HepG2 cells by gene targeting. J Clin Invest 1992;90:256-261.
82. Itzhaki JE, Gilbert CS, Porter AC. Construction by gene targeting in human cells of a "conditional" CDC2 mutant that rereplicates its DNA. Nat Genet 1997;15:258-265.
83. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-88.
84. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-237.
85. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-141.
86. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3s is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-620.
87. Rhee I, Jair KW, Yen RW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003-1007.
88. Jallepalli PV, Waizenegger IC, Bunz F, et al. Securin is required for chromosomal stability in human cells. Cell 2001;105:445-457.
89. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416: 552-556.
90. Yoshihara T, Ishida M, Kinomura A, et al. XRCC3 defi ciency results in a defect in recombination and increased endoreduplication in human cells. EMBO J 2004;23:670-680.
91. Masramon L, Ribas M, Cifuentes P, et al. Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet Cytogenet 2000;121:17-21.
92. Abdel-Rahman WM, Katsura K, Rens W, et al. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci USA 2001;98:2538-2543.
93. Myung K, Ghosh G, Fattah FJ, et al. Regulation of telomere length and suppression of genomic instability in human somatic cells by Ku86. Mol Cell Biol 2004;24:5050-5059.
94. Giannini G, Ristori E, Cerignoli F, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-254.
95. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-1629.
96. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995;9:48-55.
97. Mellon I, Rajpal DK, Koi M, Boland CR, Champe GN. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 1996;272:557-560.
98. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000;290: 989-992.
99. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of b-catenin mutation. Proc Natl Acad Sci USA 2002;99:8265-8270.
100. Uegaki K, Adachi N, So S, Iiizumi S, Koyama H. Heterozygous inactivation of human Ku70/Ku86 heterodimer does not affect cell growth, double-strand break repair, or genome integrity. DNA Repair 2006;5:303-311.
101. So S, Adachi N, Lieber MR, Koyama H. Genetic interactions between BLM and DNA ligase IV in human cells. J Biol Chem 2004;279:55433-55442.
102. Hurwitz R, Hozier J, LeBien T, et al. Characterization of a leukemic cell line of the pre-B phenotype. Int J Cancer 1979;23:174-180.
103. Wlodarska I, Aventin A, Ingles-Esteve J, et al. A new subtype of pre-B acute lymphoblastic leukemia with t(5;12)(q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in chronic myelomonocytic leukemia. Blood 1997;89:1716-1722.
104. Matheson EC, Hall AG. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis 2003;24:31-38.
105. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965;149:754-756.
106. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992;158:97-129.
107. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specifi c integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87:2211-2215.
108. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adenoassociated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-3950.
109. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy-a review. Stem Cells Dev 2004;13:133-145.
110. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005;99:119-145.
111. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968;40:319-327.
112. Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol 1981;40:241-247.
113. Rose JA, Berns KI, Hoggan MD, Koczot FJ. Evidence for a singlestranded adenovirus-associated virus genome: Formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci USA 1969;64:863-869.
114. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987;61: 3096-3101.
115. Johnson FB, Ozer HL, Hoggan MD. Structural proteins of adenovirus-associated virus type 3. J Virol 1971;8:860-863.
116. Rose JA, Maizel JV Jr, Inman JK, Shatkin AJ. Structural proteins of adenovirus-associated viruses. J Virol 1971;8:766-770.
117. Lusby E, Fife KH, Berns KI. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J Virol 1980;34: 402-409.
118. Xiao X, Xiao W, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 1997;71:941-948.
119. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol 1989;63:3822-3888.
120. Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med 1997;3:1295-1297.
121. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-2232.
122. Russwll DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet 1998;18:325-330.
123. Chamberlain JR, Schwarze U, Wang PR, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004;303:1198-1201.
124. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res 2004;32: e3.
125. Itzhaki JE, Porter AC. Targeted disruption of a human interferoninducible gene detected by secretion of human growth hormone. Nucleic Acids Res 1991;19:3835-3842.
126. Itzhaki JE, Barnett MA, MacCarthy AB, Buckle VJ, Brown WR, Porter AC. Targeted breakage of a human chromosome mediated by cloned human telomeric DNA. Nat Genet 1992;2:283-287.
127. Porter AC, Itzhaki JE. Gene targeting in human somatic cells. Complete inactivation of an interferon-inducible gene. Eur J Biochem 1993;218:273-281.
128. Culver KW, Hsieh WT, Huyen Y, et al. Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides. Nat Biotechnol 1999;17:989-993.
129. Kim JS, Lee C, Foxworth A, Waldman T. B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res 2004;64:1932-1937.
130. Kunzelmann K, Legendre JY, Knoell DL, Escobar LC, Xu Z, Gruenert DC. Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther 1996;3:859-867.
131. Zhen L, King AA, Xiao Y, Chanock SJ, Orkin SH, Dinauer MC. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc Natl Acad Sci USA 1993;90:9832-9836.
132. Song KY, Schwartz F, Maeda N, Smithies O, Kucherlapati R. Accurate modification of a chromosomal plasmid by homologous recombination in human cells. Proc Natl Acad Sci USA 1987;84: 6820-6824.
133. Thyagarajan B, Johnson BL, Campbell C. The effect of target site transcription on gene targeting in human cells in vitro. Nucleic Acids Res 1995;23:2784-2790.
134. Kim JS, Crooks H, Dracheva T, et al. Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002;62:2744-2748.
135. Hiyama T, Katsura M, Yoshihara T, et al. Haploinsuffi ciency of the Mus81-Eme1 endonuclease activates the intra-S-phase and G2/M checkpoints and promotes rereplication in human cells. Nucleic Acids Res 2006;34:880-892.
136. Dhar SK, Yoshida K, Machida Y, et al. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 2001;106:287-296.
137. Zhou S, Buckhaults P, Zawel L, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor b and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 1998;95:2412-2416.
138. Hirata RK, Russell DW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol 2000;74:4612-4620.
139. Inoue N, Dong R, Hirata RK, Russell DW. Introduction of single base substitutions at homologous chromosomal sequences by adenoassociated virus vectors. Mol Ther 2001;3:526-530.
140. Dang LH, Chen F, Knock SA, et al. CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45. Oncogene 2006;25:2048-2059.
141. Dang LH, Chen F, Ying C, et al. CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48. Oncogene 2006;25:2264-2272.
142. Porteus MH, Cathomen T, Weitzman MD, Baltimore D. Effi cient gene targeting mediated by adeno-associated virus and DNA doublestrand breaks. Mol Cell Biol 2003;23:3558-3565.
143. Liu X, Yan Z, Luo M, et al. Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions. J Virol 2004;78:4165-4175.
144. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: Disruption of HAUSP gene stabilizes p53. Nature 2004;428:1.
145. Hirata R, Chamberlain J, Dong R, Russell DW. Targeted transgene insertion into human chromosomes by adeno-associated virus vectors. Nat Biotechnol 2002;20:735-738.
146. Inoue N, Hirata RK, Russell DW. High-fidelity correction of mutations at multiple chromosomal positions by adeno-associated virus vectors. J Virol 1999;73:7376-7380.
147. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650-1653.
148. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004;64:3006-3008.